"
The Efficacy and Safety of Yokukansankachimpihange for Treating Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: An Open-Label Pilot Study"
written by Ryutaro Arita, Tetsuhiro Yoshino, Miwako Ohgishi, Takuya Hamaguchi, Yuko Horiba, Kaori Sawai, Kei Funaki, Hajime Tabuchi, Mizuki Oka, Takahito Yoshizaki, Kenji Watanabe, Masaru Mimura,
published by
Advances in Alzheimer's Disease,
Vol.7 No.4, 2018
has been cited by the following article(s):
[1]
|
Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment
YAKUGAKU ZASSHI,
2021
DOI:10.1248/yakushi.21-00003
|
|
|
[2]
|
Yokukansankachimpihange Improves the Social Isolation-Induced Sleep Disruption and Allopregnanolone Reduction in Mice
Frontiers in Nutrition,
2020
DOI:10.3389/fnut.2020.00008
|
|
|
[3]
|
Yokukansankachimpihange, a traditional Japanese (Kampo) medicine, enhances the adaptation to circadian rhythm disruption by increasing endogenous melatonin levels
Journal of Pharmacological Sciences,
2020
DOI:10.1016/j.jphs.2020.08.001
|
|
|
[4]
|
Comparison of the Effects of Yokukansan and Yokukansankachimpihange on Glutamate Uptake by Cultured Astrocytes and Glutamate-Induced Excitotoxicity in Cultured PC12 Cells
Evidence-Based Complementary and Alternative Medicine,
2019
DOI:10.1155/2019/9139536
|
|
|